Click for contact details


6th June 2013
Alliance Pharma acquires global rights to Syntometrine from Novartis
Alliance Pharma plc has acquired all existing rights to SyntometrineTM from Novartis AG and Novartis Pharma AG (together "Novartis") for a consideration of US$11.5 million.
Read this article

7th May 2013
Graham Cox to join eZono as CEO
eZono’s supervisory board has appointed Graham D. Cox as the company’s Chief Executive Officer effective 1st June 2013. Mr. Cox will succeed Allan R. Dunbar, co-founder and acting CEO of eZono, who remains with the company as Chief Commercial Officer.
Read this article

29th April 2013
Cara partners with Maruishi for Japanese rights to CR845
Cara Therapeutics, Inc. and Maruishi Pharmaceutical Company, Ltd. (Maruishi) today announced that they have entered into a License Agreement providing Maruishi with exclusive rights to develop, manufacture and commercialize Cara’s lead analgesic drug candidate, CR845, for acute pain and uremic pruritus in Japan.
Read this article

22nd April 2013
Horizon Discovery Announces Oncology Drug Discovery Collaboration with AstraZeneca
Horizon Discovery (Horizon) and AstraZeneca have entered into an exclusive collaboration and license agreement to explore Horizon’s first-in-class kinase target programme, HD-001, as a means of developing novel therapies for multiple cancer types.
Read this article

19th March 2013
Biovex Phase III trial meets primary endpoint
• Biovex’s acquirer Amgen announces Phase III trial of talimogene laherparepvec in melanoma has met its primary endpoint
Read this article

News Archive
Last 5 Articles | Next 5 Articles

Article image
 16th October 2007
Evotec Reports Positive Top-Line Results in Phase II Study with EVT 201 in Elderly Insomniacs with Daytime Sleepiness

Evotec AG has announced positive top-line results from its second phase II trial of EVT 201 in 149 elderly primary insomnia patients with daytime sleepiness.

The study showed a highly significant improvement between both doses of EVT 201 and placebo on the primary endpoint of polysomnography (PSG) derived Total Sleep Time (TST).

Compared to placebo, mean TST increased by 30.9 minutes (9%) on EVT 201 1.5 mg and 56.4 minutes (17%) on EVT 201 2.5 mg; p=0.0001 and p=<0.0001 respectively.

Significant improvements were also seen across key PSG-derived secondary endpoints including Wake After Sleep Onset (WASO) and Latency to Persistent Sleep (LPS).

Although the study was not powered to show this, the 2.5 mg dose also showed a significant effect on TWT (Total Wake Time) during the second half of the night, indicating that EVT 201 is highly effective in maintaining sleep throughout the night.

Associated Links
Visit Evotec AG
Full Press Release